Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ImunoVitg is a traditional medicine and dietary supplement developed and manufactured by the Indonesian company Royal Medicalink Pharmalab. Classified as an Indonesian Modern Natural Medicine (OMAI), it is formulated to enhance and maintain the body's immune system. The product's primary active components include *Channa striata* (corkfish) extract, which is rich in albumin and essential amino acids that facilitate tissue regeneration and immune protein synthesis; *Phyllanthus niruri* (meniran) extract, which acts as an immunomodulator by increasing the activity of macrophages and natural killer cells; and *Curcuma xanthorrhiza* (temulawak) extract, which provides antioxidant, anti-inflammatory, and hepatoprotective benefits. ImunoVitg is typically used as a consumer health product for general immune support and to aid in the recovery process following illness or surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ImunoVitg.